Article info
Clinical and epidemiological research
Concise report
Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars
- Correspondence to Dr Daniel Nagore, Progenika-Grifols, 504 Parque Tecnológico Bizkaia, Derio 48160 Spain; daniel.nagore{at}progenika.grifols.com
Citation
Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars
Publication history
- Received September 29, 2015
- Revised February 16, 2016
- Accepted February 21, 2016
- First published March 10, 2016.
Online issue publication
August 10, 2016
Article Versions
- Previous version (10 March 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/